Mekata Eiji, Sonoda Hiromichi, Shimizu Tomoharu, Tatsuta Takeshi, Yamaguchi Tomohiro, Endo Yoshihiro, Tani Tohru
Department of Surgery, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Mol Clin Oncol. 2013 Jul;1(4):763-767. doi: 10.3892/mco.2013.102. Epub 2013 Apr 11.
Clinically useful predictors of the efficacy of adjuvant chemotherapy following curative colorectal surgery remain to be determined. In the present study, we investigated the clinical utility of the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) as a predictor of the therapeutic response to 5-fluorouracil (5-FU)-based adjuvant chemo-therapy in patients with stage II-III colorectal cancer. CD-DST was conducted using tumor samples surgically obtained from 189 patients. The therapeutic effect of 5-FU-based regimens between high (high-group) and low (low-group) sensitivity groups and a group that did not receive chemotherapy [CTx(-) group] was compared. CD-DST was successfully performed in 151 out of the 189 patients (79.9%), 87 of whom received 5-FU-based adjuvant chemotherapy after surgery. Twenty-seven of these 87 patients (31.0%) were classified as the high-group and the remaining 60 (69.0%) as the low-group. The 5-year recurrence-free survival (RFS) in the high-group was significantly higher compared to that in the low- and the CTx(-) groups. No differences in the 5-year RFS were observed between the low- and CTx(-) groups. In conclusion, CD-DST appears to be useful for predicting the therapeutic response to 5-FU-based adjuvant chemotherapy in patients with stage II-III colorectal cancer.
根治性结直肠癌手术后辅助化疗疗效的临床有用预测指标仍有待确定。在本研究中，我们调查了胶原凝胶微滴包埋培养药物敏感性试验（CD-DST）作为II-III期结直肠癌患者对基于5-氟尿嘧啶（5-FU）的辅助化疗治疗反应预测指标的临床实用性。使用从189例患者手术获取的肿瘤样本进行CD-DST。比较了高敏感性组（高敏组）、低敏感性组（低敏组）和未接受化疗组[CTx(-)组]之间基于5-FU方案的治疗效果。189例患者中有151例（79.9%）成功进行了CD-DST，其中87例在术后接受了基于5-FU的辅助化疗。这87例患者中，27例（31.0%）被归类为高敏组，其余60例（69.0%）为低敏组。高敏组的5年无复发生存率（RFS）显著高于低敏组和CTx(-)组。低敏组和CTx(-)组之间未观察到5年RFS的差异。总之，CD-DST似乎有助于预测II-III期结直肠癌患者对基于5-FU的辅助化疗的治疗反应。
